Medical devices, healthcare technology and the business of care
PMA approval · P250029

SimpleScreen CRC

Freenome, LLC · Decision date Jul 24, 2026

FDA DECISIONP250029

What did the FDA approve?

FDA records P250029 as an original PMA application. The recorded decision is approval, dated Jul 24, 2026.

FDA approval order statement

The SimpleScreen CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit.SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Jul 24, 2026

FDA source record

Regulatory record facts

Identifier
P250029
Regulatory pathway
Premarket approval application
Applicant
Freenome, LLC
Product code
PHP
Decision code
APPR
Decision date
Jul 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.

Applicant
Freenome, LLC
Product code
PHP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250029 received

    Application receipt date recorded by FDA.

  2. P250029 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250029

Product / regulatory recordCompanyPathwayDecision dateSource
SimpleScreen CRCP250029/S003
Freenome, LLCPMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code PHP

Product / regulatory recordCompanyPathwayDecision dateSource
ShieldP230009/S021
Guardant Health, Inc.PMA supplementOct 5, 2026FDA
ShieldP230009/S020
Guardant Health, Inc.PMA supplementSep 16, 2026FDA
ShieldP230009
Guardant Health, Inc.PMA approvalJul 26, 2024FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Freenome, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Bldg. 1, 3300 Marina Blvd., Brisbane, CA, 94005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records